Aramchol is primarily investigated for its potential in treating non-alcoholic steatohepatitis (NASH), a severe form of fatty liver disease. It works by reducing liver fat accumulation and improving metabolic parameters, making it a promising candidate for addressing this condition. Additionally, Aramchol has shown efficacy in improving insulin sensitivity, which could benefit patients with type 2 diabetes or metabolic syndrome. Its mechanism involves modulating lipid metabolism, which also supports its potential use in managing cholesterol levels and related cardiovascular risks. Clinical trials continue to explore its broader therapeutic applications in metabolic and liver disorders.